NCT06487247Recruiting
HEME Home Transfusion Program
Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- First submitted
- 27 Jun 2024
- Start date
- 10 Sept 2025
- Primary completion date
- 31 May 2029
- Lead sponsor
- Dana-Farber Cancer Institute
- NCT number
- NCT06487247
What you commit to
- Study type: Interventional
- Planned participants: 700
- From 10 Sept 2025 to the primary completion date, 31 May 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous serious adverse transfusion reaction
Age
- Age \< 18 years
- -Age \< 18 years
Other
- Already enrolled in hospice
- Resides in nursing home or assisted living facility
Who the study is looking for
- Diagnosis of a relapsed/refractory hematologic malignancy
- Age ≥ 18 years
- Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
- Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
- Patient resides within catchment served by Care Dimensions Hospice
- Physician-estimated prognosis of six months or less
- Identified informal caregiver of enrolled patient with hematologic malignancy
- Age ≥ 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.